MAPT and Alzheimer disease: Multiple studies have focused on the development of Aβ and tau biomarkers to track the progression of AD, revealing that Aβ deposition is one of the earliest events, followed by tau accumulation (Jack et al., 2013; Selkoe and Hardy, 2016; Jack et al., 2018).